<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75535">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887444</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00163-42</org_study_id>
    <nct_id>NCT01887444</nct_id>
  </id_info>
  <brief_title>Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic</brief_title>
  <acronym>PROBIOC</acronym>
  <official_title>The Benefit of Using the Lactobacillus Reuteri Probiotic as a Supplement in the Treatment of Newborn Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRC CHI Creteil France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association Clinique et therapeutique infantile du Val de Marne ACTIV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robert Debré Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the oral administration of
      Lactobacillus reuteri in treating infantile colic as defined by the Rome III criteria. Forty
      breastfed infants aged from 29 days to 3 months will be enrolled and blinded randomized to
      receive orally L.reuteri or placebo. The rate of responders (reduction of daily crying time
      &gt;50% compared to the baseline) will be assessed at day 7, day 14 and day 21 in both groups.
      The average daily crying time as well as the associated digestive symptoms will also be
      analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The responder rate (infants for whom daily crying time decreases by 50% compared to baseline, D0) at D7 in the probiotic group compared to placebo. The daily crying time will be sound recorded during 24 hours at D0 and D7.and expressed in minutes.</measure>
    <time_frame>day 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The responders rates at D14 and D21 in the probiotic group compared to the placebo group.</measure>
    <time_frame>Day 14 and day 21</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The average duration of crying in the probiotic group compared with the placebo group at D7, D14 and D21.</measure>
    <time_frame>Day 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal symptoms (constipation, diarrhea, flatulence) evaluated at each visit required by the protocol</measure>
    <time_frame>day 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infantile Colic</condition>
  <arm_group>
    <arm_group_label>Lactobacillus reteuri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement:   Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Other:   Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM17938 probiotic</intervention_name>
    <description>Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.</description>
    <arm_group_label>Lactobacillus reteuri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Exclusively breastfed Infants

          2. Infant aged of 29 days to 3 months

          3. With a diagnosis of infantile colic as defined by the Rome III criteria

          4. Birth at term and eutrophic (weight, height, head circumference)

          5. Apgar score&gt; 7 at 5 minutes

          6. Consent to the study signed by the two parents.

          7. Availability during the study period

        Exclusion Criteria:

          1. Associated severe chronic disease

          2. Acute infectious disease

          3. Personal or family first degree history of allergy to milk proteins

          4. Several infants of the same family from a multiple pregnancy

          5. Infants who received antibiotics one week prior to randomization

          6. Infants who received probiotics one week prior to randomization

          7. Mother who received antibiotics 1 week before randomization

          8. Regular consumption of probiotics by the mother 1 week before randomization

          9. Infants-included in another clinical study

         10. Lack of insurance coverage by the french social security

         11. Non exclusively breastfed infants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bellaiche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Debré Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC CHIC and ACTIV</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille JUNG, MD PhD</last_name>
      <phone>+33157022268</phone>
      <email>camille.jung@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Bellaiche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pediatricians members of the ACTIV association, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Gastroenterology</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Lactobacillus reuteri</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
